Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Emerging Research on Primary Brain Tumors
share announcement

Emerging Research on Primary Brain Tumors

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 2151

Special Issue Editors

Dr. Jacob S Young

E-Mail Website
Guest Editor
Department of Neurosurgery, University of California San Francisco, San Francisco, CA 94131, USA
Interests: glioma; brain tumors; brain mapping; awake craniotomy; extent of resection
Prof. Dr. Mitchel S. Berger

E-Mail Website
Guest Editor
Department of Neurosurgery, University of California San Francisco, San Francisco, CA 94131, USA
Interests: glioma; brain tumors; brain mapping; awake craniotomy; extent of resection

Special Issue Information

Dear Colleagues,

Despite tremendous surgical, technological, and therapeutic advances, the prognosis for most patients with malignant gliomas remains poor. Moreover, there remains no effective standard of care for recurrent disease, and even for patients with IDH-mutant lower-grade gliomas, many treatment options can significantly worsen their quality of life.

Over the past few decades, great efforts have been made to improve diagnostic accuracy and personalized treatment options. Molecular biomarkers have been investigated, and new classifications have been proposed to better account for tumor behavior. At the same time, new surgical, pharmacological, and immunological strategies have been developed to improve treatment outcomes. Nevertheless, many issues facing targeted or immunological therapy remain.

This Special Issue of Cancers will cover all aspects of neurological cancers, including original research into advanced imaging, molecular characterization, surgical approaches, current and experimental drug delivery options, and strategies to improve quality of life. Expert opinions, systematic reviews, and meta-analyses are also welcome.

Dr. Jacob S Young
Prof. Dr. Mitchel S. Berger
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • molecular biomarkers
  • drug delivery
  • immunotherapy
  • personalized medicine
  • targeted therapies
  • glioma

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

18 pages, 2800 KiB  
Article
Microvascular Cortical Dynamics in Minimal Invasive Deep-Seated Brain Tumour Surgery
by José Pedro Lavrador, Oliver Wroe-Wright, Francesco Marchi, Ali Elhag, Andrew O’Keeffe, Pablo De La Fuente, Christos Soumpasis, Andrea Cardia, Ana Mirallave-Pescador, Alba Díaz-Baamonde, Jose Sadio Mosquera, Domingos Coiteiro, Sharon Jewell, Anthony Strong, Richard Gullan, Keyoumars Ashkan, Francesco Vergani, Ahilan Kailaya Vasan and Ranjeev Bhangoo
Cancers 2025, 17(9), 1392; https://doi.org/10.3390/cancers17091392 - 22 Apr 2025
Viewed by 305
Abstract
Background: The tubular retractor-assisted minimally invasive parafascicular approach (trMIPS) is a transsulcal approach to deep-seated brain tumours. It is a safe surgical approach but its impact on the microvascular dynamics of the retracted cortex and its clinical implications are unknown. Methods: This was [...] Read more.
Background: The tubular retractor-assisted minimally invasive parafascicular approach (trMIPS) is a transsulcal approach to deep-seated brain tumours. It is a safe surgical approach but its impact on the microvascular dynamics of the retracted cortex and its clinical implications are unknown. Methods: This was a single-centre prospective study including patients with deep-seated brain tumours operated on with a trMIPS (BrainPath Nico System©). All patients underwent pre- and post-cannulation indocyanine green study using a FLOW 800 module in a KINEVO Zeiss© microscope. Speed, delay, time-to-peak (TtP) rise-in-time and cerebral blood flow index (CBFI) metrics were assessed. Results: Thirty-five patients were included, with 144 regions-of-interest (ROIs) selected. The majority of patients were diagnosed with glioblastoma (51.43%), and 37.14% of patients had a preoperative focal neurological deficit (FND) at presentation. A ROI-based analysis concluded that an increase in speed and CBFI was related with a worse neurological outcome when comparing the pre- and post-brain cannulation assessments (speed: deterioration = 43.12 ± 80.60% versus stable = −14.51 ± 57.80% versus improvement = 6.93 ± 31.33%, p < 0.0001; CBFI: deterioration = 50.40 ± 88.17% versus stable = −2.70 ± 67.54% versus improvement = −38.98 ± 26.17%, p = 0.0005). These findings were reproducible in a combined-ROI per patient analysis and confirmed after adjustment for confounding. Conclusion: Microvascular flow dynamics impact trMIPS outcomes as an increase in the speed and CBFI after decannulation was related with worse neurological outcome. Full article
(This article belongs to the Special Issue Emerging Research on Primary Brain Tumors)
►▼ Show Figures

Figure 1

Review

Jump to: Research

11 pages, 506 KiB  
Review
Latest Advancements in the Management of H3K27M-Mutant Diffuse Intrinsic Pontine Glioma: A Narrative Review
by Maria Chiara Lo Greco, Giorgia Marano, Madalina La Rocca, Grazia Acquaviva, Roberto Milazzotto, Rocco Luca Emanuele Liardo, Antonio Basile, Pietro Valerio Foti, Stefano Palmucci, Emanuele David, Silvana Parisi, Antonio Pontoriero, Stefano Pergolizzi and Corrado Spatola
Cancers 2025, 17(3), 420; https://doi.org/10.3390/cancers17030420 - 27 Jan 2025
Cited by 1 | Viewed by 1373
Abstract
Despite recent advancements in radiotherapy for Diffuse Intrinsic Pontine Glioma (DIPG), the prognosis of this disease remains poor, highlighting the need for new treatment strategies to improve outcomes. Adding stereotactic biopsy to the diagnostic process for children with DIPG has been crucial in [...] Read more.
Despite recent advancements in radiotherapy for Diffuse Intrinsic Pontine Glioma (DIPG), the prognosis of this disease remains poor, highlighting the need for new treatment strategies to improve outcomes. Adding stereotactic biopsy to the diagnostic process for children with DIPG has been crucial in improving the management of this disease. Indeed, the discovery of the H3K27M mutation as a key driver of DIPG has led to the development of new drugs that are more effective than traditional ones. These include nimotuzumab (an anti-EGFR drug) and vinorelbine (a semisynthetic vinca alkaloid) in combination, Panobinostat (a histone deacetylase inhibitor), ONC201 (a drug that blocks the dopamine receptor D2 and inactivates Akt and ERK kinases), and chimeric antigen receptor (CAR) T cells. In terms of local therapy, identifying the H3K27M mutation can help us explore how genetic changes affect treatment response, recurrence patterns, and survival. Beyond the time to first recurrence, specific patterns of tumor recurrence, like leptomeningeal spread, can influence treatment plans. For example, radiotherapy can be adjusted in terms of doses and volumes, based on tumor aggressiveness. Because the H3K27M mutation is linked to higher malignancy, a slightly higher dose could be used for the second round of local irradiation. Additionally, irradiating the entire craniospinal axis could help control both local and leptomeningeal disease. Full article
(This article belongs to the Special Issue Emerging Research on Primary Brain Tumors)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop